Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Anastrozole benefits confirmed in postmenopausal breast cancer patients
January 13th, 2005
Postmenopausal women with hormone-sensitive breast cancer receive an increased benefit from treatment with the aromatase inhibitor anastrozole compared with tamoxifen, according to two papers presented at the 27th Annual San Antonio Breast Cancer Symposium. Benefits were seen whether anastrozole was given as a primary treatment for 5 years, or as an additional treatment after 2 years of tamoxifen. Aromatase inhibitors deplete circulating estrogen in postmenopausal women, shutting down the principal cell signaling pathway in the pathogenesis of breast cancer. Tamoxifen, in comparison, exerts its effect by interacting with the estrogen receptor. ...
Source: Women's Health Weekly (2005-01-13)
|
